Huang Yunhe, Liu Yunkun, Zou Wei, Mao Na, Tang Jian, Jiang Lei, Zou Guowen, Yang Lun, Yu Bentong, Wei Guangxia
Department of Thoracic Surgery, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Front Surg. 2023 Feb 24;10:1144299. doi: 10.3389/fsurg.2023.1144299. eCollection 2023.
Endoscopic thoracoscopic sympathectomy (ETS) is the preferred method for treating primary palmar hyperhidrosis (PPH) that bears the risk of compensatory hyperhidrosis (CH) following surgery. The current study aims to evaluate the effectiveness and safety of an innovative surgical procedure of ETS.
A survey of the clinical data of 109 patients with PPH who underwent ETS in our department from May 2018 to August 2021 was retrospectively conducted. The patients were organized into two groups. Group A underwent R4 sympathicotomy combined with R3 ramicotomy. Group B underwent R3 sympathicotomy. Patients were followed up to evaluate the safety, effectiveness and the incidence of postoperative CH of the modified surgical approach.
A total of 102 patients completed follow-up, and seven of the total enrolled patients were lost to follow-up, with a loss rate of 6% (7/109). Among these, Group A constitutes 54 cases, group B constitutes 48 cases, and the mean follow-up was 14 months (interquartile range 12-23 months). There was no statistically difference in surgical safety, postoperative efficacy, and postoperative quality of life (QoL) score between group A and group B ( > 0.05). The score of the psychological assessment was higher ( = 0.004) in group A (14.15 ± 2.06) compared to group B (13.30 ± 1.86). The incidence of CH in group A was lower than in group B ( = 0.019).
R4 sympathicotomy combined with R3 ramicotomy is safe and effective for PPH treatment, along with a reduced incidence of postoperative CH rate and improved postoperative psychological satisfaction.
胸腔镜交感神经切除术(ETS)是治疗原发性手掌多汗症(PPH)的首选方法,但该手术存在术后代偿性多汗(CH)的风险。本研究旨在评估一种创新的ETS手术方法的有效性和安全性。
回顾性调查了2018年5月至2021年8月在我科接受ETS治疗的109例PPH患者的临床资料。将患者分为两组。A组行R4交感神经切断术联合R3分支切断术。B组行R3交感神经切断术。对患者进行随访,以评估改良手术方法的安全性、有效性和术后CH的发生率。
共有102例患者完成随访,总入组患者中有7例失访,失访率为6%(7/109)。其中,A组54例,B组48例,平均随访时间为14个月(四分位间距12 - 23个月)。A组和B组在手术安全性、术后疗效和术后生活质量(QoL)评分方面无统计学差异(>0.05)。A组(14.15±2.06)的心理评估得分高于B组(13.30±1.86)(=0.004)。A组CH的发生率低于B组(=0.019)。
R4交感神经切断术联合R3分支切断术治疗PPH安全有效,可降低术后CH发生率并提高术后心理满意度。